MacroGenics Announces Sale of TZIELD™ Royalty Interest for

MacroGenics Announces Sale of TZIELD™ Royalty Interest for

ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and......

MacroGenics Announces Date of Fourth Quarter 2022 Financial

MacroGenics Announces Date of Fourth Quarter 2022 Financial

ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and......

MacroGenics to Participate in Upcoming Investor

MacroGenics to Participate in Upcoming Investor

ROCKVILLE, MD, Feb. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing......

menu
menu